<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557319</url>
  </required_header>
  <id_info>
    <org_study_id>CIR-HAET-I</org_study_id>
    <secondary_id>#725 eff date 20.12.2019</secondary_id>
    <nct_id>NCT04557319</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers</brief_title>
  <official_title>An Open Study of the Safety and Pharmacokinetics of GNR-038 in Sequential Dose-increase Cohorts in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an open-label dose-escalating study in sequential cohorts to assess safety and&#xD;
      pharmacokinetics of GNR-038.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary angioedema (HAE) is a rare potentially life-threatening genetically determined&#xD;
      disease associated with a deficiency or impairment of C1 esterase inhibitor (C1 inhibitor)&#xD;
      functional activity. Main clinical manifestations of HAE are recurrent mucous membranes edema&#xD;
      and localization of the derma deep layers. Attack persist from several hours to several days&#xD;
      and disappear without a trace in most cases, without additional therapy.&#xD;
&#xD;
      The prevalence of the disease in the world is from 1:10 000 to 1: 150 000. The&#xD;
      plasma/recombinant C1 inhibitor use to compensate for its deficiency or insufficient&#xD;
      functional activity in patients with HAE is recommended both for severe and for long-term and&#xD;
      short-term (before surgical interventions and dental manipulations) prophylaxis.&#xD;
&#xD;
      GNR-038 is a recombinant C1 inhibitor (rhC1-inh), which is a complete structural and&#xD;
      functional analogue of the plasma C1 inhibitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Actual">August 27, 2020</completion_date>
  <primary_completion_date type="Actual">August 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose-increase cohorts in healthy volunteers</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>28 Days</time_frame>
    <description>Adverse events, Laboratory tests, Vital signs, Physical examination, 12-lead electrocardiogram, Allergic associated reaction, Infusion associated reaction, Antidrug antibody.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>45, 30 and 15 minutes before GNR-038 infusion; 0, 15, 30 minutes, 1, 2, 4, 8,12,16, 24, 48, 72, 96, 120,144 and 168 hours after GNR-038 infusion</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean retention time (MRT)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall clearance (Cl)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic volume of distribution (Vz)</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>GNR-038, 25 МЕ/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-038, 50 МЕ/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNR-038, 100 МЕ/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-038, 25 МЕ/kg</intervention_name>
    <description>25 МЕ/kg once per study</description>
    <arm_group_label>GNR-038, 25 МЕ/kg</arm_group_label>
    <other_name>rC1inh, 25 МЕ/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-038, 50 МЕ/kg</intervention_name>
    <description>50 МЕ/kg once per study</description>
    <arm_group_label>GNR-038, 50 МЕ/kg</arm_group_label>
    <other_name>rC1inh, 50 МЕ/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-038, 100 МЕ/kg</intervention_name>
    <description>100 МЕ/kg once per study</description>
    <arm_group_label>GNR-038, 100 МЕ/kg</arm_group_label>
    <other_name>rC1inh, 100 МЕ/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Men and women aged 18 to 50 (inclusive) at the time of signing the Informed Consent&#xD;
             Form.&#xD;
&#xD;
          2. Body mass index (BMI) in the range from 18.5 to 30 kg / m2, body weight from 50 to 90&#xD;
             kg.&#xD;
&#xD;
          3. The diagnosis is &quot;healthy&quot; according to the data of clinical and biochemical blood&#xD;
             tests, urinalysis, results of physical examination, measurement of vital signs,&#xD;
             results of electrocardiography.&#xD;
&#xD;
          4. Availability of written informed consent obtained from the volunteer prior to any&#xD;
             research-related procedures performance.&#xD;
&#xD;
          5. Consent to follow the adequate contraceptive methods.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Known hypersensitivity to the components of the study drug;&#xD;
&#xD;
          2. Burdened allergic history;&#xD;
&#xD;
          3. Standard laboratory and instrumental parameters values are outside the normal range;&#xD;
&#xD;
          4. Cardiovascular, bronchopulmonary, neuroendocrine systems chronic diseases, as well as&#xD;
             gastrointestinal tract, liver, kidneys, hematopoietic, immune systems diseases, mental&#xD;
             illness;&#xD;
&#xD;
          5. Diseases and conditions associated with thrombosis (myocardial infarction, transient&#xD;
             ischemic attacks, deep and superficial vein thrombosis, pulmonary embolism) less than&#xD;
             6 months before the screening period start, as well as an increased risk of arterial&#xD;
             or venous thrombosis according to the investigator opinion.&#xD;
&#xD;
          6. Infection with human immunodeficiency virus (HIV), hepatitis B and C;&#xD;
&#xD;
          7. Acute infectious diseases less than 4 weeks prior to the Screening Visit;&#xD;
&#xD;
          8. Regular medication intake less than 2 weeks prior to the Screening Visit;&#xD;
&#xD;
          9. For women - the hormonal contraceptives use or hormone replacement therapy for 3&#xD;
             months before the screening period start;&#xD;
&#xD;
         10. Systolic pressure less than 100 mmHg or above 140 mmHg; diastolic pressure less than&#xD;
             70 mmHg or above 90 mmHg; pulse rate less than 60 beats/min or more than 90 beats/min;&#xD;
&#xD;
         11. Blood donation (450 ml of blood or plasma and more) less than 3 months before the&#xD;
             Screening Visit;&#xD;
&#xD;
         12. Participation in clinical trials less than 3 months before the Screening Visit;&#xD;
&#xD;
         13. More than 10 alcohol units intake per week (1 unit of alcohol is equivalent to 1/2&#xD;
             liter of beer, 200 ml of wine or 50 ml of ethanol) OR anamnestic information about&#xD;
             alcoholism, detection of ethanol in exhaled air;&#xD;
&#xD;
         14. Drug addiction, substance abuse, positive urine test for the content of potent and&#xD;
             narcotic drugs;&#xD;
&#xD;
         15. Smoking more than 10 cigarettes a day;&#xD;
&#xD;
         16. Pregnancy or breastfeeding;&#xD;
&#xD;
         17. Other reasons that prevent the volunteer from study participating or create an&#xD;
             unreasonable risk in the investigator opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oksana A. Markova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AO GENERIUM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State budgetary institution of healthcare of the city of Moscow &quot;Сity polyclinic No. 2 of the Department of healthcare of the city of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117556</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioedema</keyword>
  <keyword>Angioedemas, Hereditary</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Urticaria</keyword>
  <keyword>Skin Diseases, Vascular</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Hypersensitivity, Immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

